

05 January 2009

Dr Carole Longson  
Director  
Health Technology Evaluation Centre  
National Institute for Health and Clinical Excellence  
Level 1A, City Tower  
Piccadilly Plaza  
Manchester  
M1 6NA



Quarry House  
Quarry Hill  
Leeds  
LS2 7UE

Tel: [REDACTED]

Dear Carole

**Patient Access Scheme for lenalidomide for the treatment of multiple myeloma**

I am writing to confirm the Department of Health's position on the Patient Access Scheme (PAS) arrangements that have been proposed by Celgene for lenalidomide in the treatment of multiple myeloma. The Department is content for NICE to consider the lenalidomide scheme as part of its technology appraisal of the drug.

Yours sincerely

[REDACTED]